OHM-11526, Antagonist of motilin receptor, CAS No.rp174680, Antagonist of motilin receptor

CAS: rp174680 Cat. No.: rp174680

GRADE & PURITY Moligand™

Specifications

Product Name

OHM-11526, Antagonist of motilin receptor, CAS No.rp174680

동의어

[Phe³,Leu¹³]motilin (porcine)

등급

Moligand™

사양 및 순도

Moligand™

작업 유형

ANTAGONIST

작동 메커니즘

Antagonist of motilin receptor

CAS

rp174680

분자 유형

Peptide

보관 및 배송

보관 조건

Room temperature

관련 대상(인간)

MLNR Tchem Motilin receptor (0 Activities)

Discover Target: MLNR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

유전 정보

• Alternate Names: [Phe³,Leu¹³]motilin (porcine)
• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

No tested applications or validated protocols are provided for OHM-11526 in the Product Data.

General starting points for small-molecule handling in assays (non-item-specific):

• Stock preparation: Dissolve in dry DMSO to 10–50 mM. Sonication and mild warming (≤40 °C) can aid dissolution if stable. Filter sterilize (0.22 µm PTFE/PVDF) for cell-based work when compatible.
• Storage of stocks: Aliquot to avoid repeated freeze–thaw; maintain desiccation and protect from light until stability is known. Track concentration and date prepared.
• Assay dilution: Add stocks to assay buffer to achieve desired final concentration, keeping DMSO at ≤0.5–1% v/v where possible. Mix thoroughly to avoid local precipitation.
• Interference controls: Include vehicle controls, detergent controls (e.g., 0.01–0.05% Tween-20) for aggregation checks, and redox/cysteine-reactivity counterscreens as relevant.

For any specific protocol (WB, IHC, IF, FC, etc.), this product is not an antibody/reagent formulated for such applications; consult general small-molecule assay best practices.

Biological Roles

Item-specific biological roles, pathways, or endogenous relevance cannot be assigned to OHM-11526 without a disclosed chemical structure or literature identity.

General guidance for small-molecule library members (non-clinical, research-only):

• Potential roles in research:
  • Chemical probe candidates for interrogating enzymatic or receptor functions after screening.
  • Tools for pathway modulation in cell or biochemical systems, subject to confirmatory target engagement studies.
  • Starting points for SAR leading to improved potency, selectivity, and physicochemical properties.
• Considerations before attributing biological activity:
  • Validate activity across orthogonal assay formats to rule out assay interference (fluorescence quenchers, redox cyclers, aggregators).
  • Assess basic ADME traits early (solubility, stability in buffer and microsomes, permeability proxies) to contextualize observed effects.
  • Evaluate cytotoxicity and off-target liabilities in relevant counterscreens.

No medical, diagnostic, or therapeutic uses are implied or supported. For any reported activities in your lab, document exact batch/lot and conditions to ensure reproducibility.

Buffer Applications

This product is a small-molecule library compound and is not itself a buffering agent. No item-specific acid/base or pKa information is available.

• Item-specific buffering/pKa data: Not specified for this item; refer to CoA/Spec Sheet.

Practical notes (general, if using in buffered assays):

• Prepare concentrated stocks in an appropriate organic solvent (commonly DMSO), then dilute into the target buffer while maintaining final organic content typically below 1–2% v/v.
• Verify compound stability in the chosen buffer over the assay timescale; monitor by LC–MS or HPLC.
• If the compound exhibits acid/base functionality once known, select buffers with pH at least ±1 unit from the pKa of the ionizable group to control ionization state.

For buffer recipes (PBS, HEPES, Tris, MOPS, etc.), consult standard references; these are outside the scope for a non-buffer reagent.

Green Alternatives

Without a disclosed structure, green chemistry guidance focuses on solvent and process choices during handling and any downstream synthesis or purification.

• Preferred stock solvent hierarchy (general):
  • Favor safer, high-performance solvents when possible: water > bio-based alcohols (EtOH, i-PrOH) > acetone/EtOAc > MeTHF/CPME > ACN > DCM/toluene.
  • For preparative work (if re-purification is needed), consider EtOAc/Heptane or 2-MeTHF as greener alternatives to DCM/Hexane.

Illustrative comparison (general; not item-specific):

• 2-MeTHF vs THF: 2-MeTHF is less miscible with water, partially bio-based, and often enables efficient extractions with lower VOC footprint; THF is fully miscible with water but forms peroxides more readily.
• EtOAc vs DCM: EtOAc is biodegradable and less toxic; DCM offers higher density for phase separations but with greater health/environmental concerns.

Operational practices:

• Minimize DMSO volumes in biological assays and validate the lowest effective organic percentage.
• Use microscale screening formats to reduce solvent consumption.
• Implement closed-vial weighing and pre-weighed aliquots to limit exposure and waste.

Note: Any substitution must respect the compound’s actual solubility/stability once structure-specific data are available.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation specifications are provided for OHM-11526. This product is supplied strictly for research use only and is not intended for human or veterinary use.

General research context (non-clinical):

• Early discovery workflows: May serve as a screening hit or reference analog during target identification and validation.
• Pre-formulation studies (if structure becomes relevant): Solubility screening, salt/cocrystal scouting, and stability profiling can inform feasibility but do not imply clinical development.
• Quality considerations: If used in method development, ensure traceability to batch/lot and retain analytical data (HPLC purity, MS, NMR) within your internal documentation.

Item-specific regulatory/designation data (USP/EP monographs, ICH impurity limits, residual solvent class): Not specified for this item; refer to CoA/Spec Sheet.

Physical Properties

Item-specific (from Product Data)

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Key physicochemical data

• Melting point (MP): Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point (BP): Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• pKa(s): Not specified for this item; refer to CoA/Spec Sheet.
• logP/logD: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility profile (water, DMSO, alcohols, chlorinated solvents): Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/practice, not item-specific)

• For library compounds of unknown polymorph/functional group, start solubilization screening with high-boiling polar aprotic solvents (e.g., DMSO, DMF) at 10–50 mM stock, then dilute into assay buffer with final organic <1–2% v/v to minimize matrix effects.
• If an acid/base functionality is suspected, adjust pH (±1–2 units around expected pKa) to test for aqueous solubility improvements. Use cosolvent and surfactant systems only as required by the assay.
• Record any observed MP/BP or spectroscopic data during intake QC to populate your LIMS, as batch-to-batch form can affect handling.

Quality and Grades

Item-specific (from Product Data)

• Grade/Purity designation: Moligand™

What this means (general explanation; not a specification)

• Moligand™ indicates inclusion in a curated small-molecule/ligand collection intended for discovery workflows (e.g., target screening, binding studies). It typically emphasizes identity traceability and suitability for research assay use rather than analytical or pharmaceutical compendial grades. Exact acceptance criteria (purity %, residual solvents, and spectral identity) are defined in the item’s CoA/Spec Sheet.

Analytical expectations (do not substitute for CoA)

• Identity confirmation: Commonly by 1H NMR and/or LC–MS; may include HRMS and HPLC/UPLC purity. Specific methods/thresholds are batch-dependent. Not specified for this item; refer to CoA/Spec Sheet.
• Stabilizers/additives: Not specified for this item; refer to CoA/Spec Sheet.
• UV profile for chromatographic use: Not specified for this item; refer to CoA/Spec Sheet.

Recommendations for users

• Capture incoming QC data (HPLC purity, MS, NMR) into your LIMS before screening campaigns.
• If your assay is UV- or fluorescence-based, evaluate the compound’s background absorbance/auto-fluorescence across assay wavelengths to pre-empt false signals.
• For orthogonal validation, procure a second batch/lot or analytically re-purify if your application is highly sensitive to trace impurities.

Reaction and Applications

Item-specific reactivity and application notes are not available due to undisclosed structure.

Practical applications for a Moligand™ library compound (general, non-item-specific):

• Primary use cases:
  • Target screening: Biochemical or biophysical binding assays (e.g., DSF/Tm shift, SPR, MST, ITC) to identify preliminary binders.
  • Phenotypic screening: Cell-based or organismal assays to observe functional outcomes; ensure DMSO tolerance and solubility checks.
  • Probe development: If a hit emerges, use as a starting point for SAR, derivatization, and ADME profiling.
• Assay setup tips:
  • Prepare a solubility/stability panel in the intended assay matrix at working concentrations; monitor via LC–MS for degradation (oxidation, hydrolysis) over 24–72 h.
  • Filter sterilize stocks for cell-based assays (0.22 µm PTFE/PVDF) if compatible; confirm no adsorption losses.
  • Include counter-screens to flag PAINS/reactive/aggregator behavior (e.g., redox cycling, thiol reactivity, detergent-sensitive inhibition).
• Orthogonal validation:
  • Use orthogonal assay modalities to mitigate mechanism-of-assay interference.
  • Confirm concentration via quantitative NMR or UV if the chromophore is known; otherwise rely on weighed-in gravimetry with hygroscopicity controls.

For structure-specific synthetic or mechanistic applications, obtain the detailed structure and functional groups from the CoA/Spec Sheet.

Reaction Conditions

No item-specific reaction conditions can be recommended for OHM-11526 because the chemical structure and functional groups are not provided.

General guidance for downstream chemistry with library compounds (non-item-specific):

• Solvent selection for derivatization is driven by functional group compatibility (e.g., polar aprotic for couplings, alcohols for acylations/transesterifications) and the compound’s solubility profile established experimentally.
• Temperature and time should be optimized via small-scale scouting, monitoring by LC–MS/HPLC. Begin with ambient to 60 °C for most couplings; use microwave acceleration cautiously after confirming stability.
• Catalysts/bases/acids: Choose according to the intended transformation and functional tolerance (e.g., Pd catalysts for C–C/C–N couplings, carbodiimides or uronium salts for amidations). Avoid harsh conditions until stability is verified.
• Workup/purification: Favor greener solvent systems (EtOAc/Heptane, MeOH/Water) where feasible; confirm recovery and integrity by orthogonal analytics (NMR, HRMS).

Any yields or condition ranges would be transformation-specific and require knowledge of the actual substrate; consult the CoA/Spec Sheet once available.

Safety and Handling

Hazard information (from Product Data)

• Signal Word: Not specified for this item; refer to SDS.
• H-Statements: Not specified for this item; refer to SDS.
• GHS Classification: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (applicable to small-molecule libraries; defer to SDS for authority)

• Use in a fume hood; avoid inhalation of dusts/vapors and contact with skin/eyes. Wear lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). For solids, minimize dust formation during weighing; for liquids, prevent aerosolization.
• Avoid incompatible reagents until structure is verified. Default to segregating from strong oxidizers, strong acids/bases, and reactive metals. Keep away from ignition sources if volatility or flammability is unknown.
• First aid (overview): In case of eye or skin contact, rinse with water for at least 15 minutes; remove contaminated clothing. If inhaled, move to fresh air. If ingested, rinse mouth; do not induce vomiting unless directed. Seek medical attention and bring SDS.
• Spill/accident response: Contain with inert absorbent (liquid) or dampen and carefully sweep (solid). Dispose via approved chemical waste streams per institutional and local regulations.
• Special risks: Unknown peroxide or polymerization hazards—store tightly closed, protect from light until hazard data are confirmed.
• Always consult the product-specific SDS supplied for your batch before use.

Solvent Selection

Solvent selection is structure- and functionality-dependent; no item-specific solubility or polarity data are provided for OHM-11526.

• Item-specific solubility: Not specified for this item; refer to CoA/Spec Sheet.

General strategy for library compounds (practice-based guidance):

• Primary stock solvents:
  • DMSO: First choice for screening stocks (10–50 mM). High solvency for diverse chemotypes; miscible with water. Watch hygroscopicity and freeze–thaw stability.
  • DMF or NMP: Alternatives when DMSO is inadequate; consider assay compatibility and cytotoxicity in cell-based screens.
• Secondary/cosolvents for method development:
  • MeOH, EtOH, i-PrOH for LC method scouting; ACN for LC–MS compatibility.
  • MTBE, EtOAc, toluene, or CH2Cl2 for extractions/recrystallizations during re-purification.
• pH-assisted dissolution:
  • Weak bases dissolve in acidic aqueous media; weak acids in basic media. Implement buffered systems to protect assay integrity.
• Avoid excessive organic in bioassays (<1–2% v/v typical). Validate stability in the chosen solvent by time-course LC–MS.

Comparison (general):

• DMSO vs ACN: DMSO dissolves more chemotypes but is more hygroscopic and less volatile; ACN is superior for LC–MS but poorer for hydrophobic solids.
• MeOH vs EtOH: MeOH higher solvency, EtOH often preferred for biocompatibility.

Storage and Reconstitution

Item-specific (from Product Data)

• Storage Conditions: Room temperature
• Shipped In: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General best practices for small-molecule library compounds (non-item-specific):

• Solid material:
  • Store tightly sealed in a dry, inert atmosphere (desiccator or dry cabinet). Protect from light until photostability is verified. Room temperature is acceptable per Product Data; if long-term storage is planned and stability is unknown, consider 2–8 °C as a precaution.
  • If hygroscopic, handle quickly and re-cap promptly; record mass changes if gravimetric dosing is used.
• Solution stocks:
  • Prepare concentrated stocks in dry DMSO (typ. 10–50 mM). Aliquot into amber vials or 96/384-well plates, seal with foil caps.
  • Minimize freeze–thaw cycles; store at −20 °C to −80 °C if long-term solution stability is required. Track lot, date, and concentration.
  • Inspect for precipitation or discoloration before use; confirm by LC–MS/HPLC if critical.
• Reconstitution: Without solubility data, begin with DMSO, then test assay-compatible diluents. Document final solvent composition used in experiments.

Always consult the batch-specific CoA/Spec Sheet and SDS for definitive handling and storage instructions.

Structure and Identity

Item-specific (from Product Data)

• SKU: rp174680
• Product Name: OHM-11526
• CAS: rp174680 (as provided)
• Grade/Purity: Moligand™
• Storage Conditions: Room temperature
• Category: Small molecules and compound libraries (全部 / 可售 / 小分子和化合物库)
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general note)

• Structural class, ring systems, functional groups, and stereochemistry are not provided for this catalog entry. Without a disclosed structure, cheminformatics descriptors (e.g., HBA/HBD counts, rotatable bonds, cLogP) cannot be summarized here.

How to reference this item

• Cite as: “OHM-11526 (Moligand™), Aladdin Scientific, SKU rp174680.” Attach the product’s CoA/Spec Sheet for structure-specific identifiers when available.

Remarks

• For any structure-dependent work (e.g., docking, QSAR, metabolism prediction), obtain the structure file (SMILES/SDF) from the batch-specific documentation or request it from Aladdin Scientific if not present in your account.

Synthetic Utility

Synthetic roles cannot be assigned without the disclosed structure or functional groups of OHM-11526.

General notes for library compounds used in synthesis method development (non-item-specific):

• If the compound is a building block or has a latent functional handle (e.g., halide, boronate, carboxylate, amine), it may participate in cross-coupling, amidation, or alkylation sequences to generate analogs for SAR.
• Protecting-group strategy and chemoselectivity should be chosen after functional group identification by NMR/IR/LC–MS.
• For parallel synthesis, design diversification points informed by the actual scaffold once known; employ robust reactions (Suzuki–Miyaura, Buchwald–Hartwig, amide couplings) to rapidly explore vectors.

Item-specific reactivity, stability, or incompatibilities: Not specified for this item; refer to CoA/Spec Sheet.

Target Specificity

Target specificity data (e.g., enzyme/receptor targets, binding constants, selectivity profiles) are not provided for OHM-11526.

• Item-specific biological target information: Not specified for this item; refer to CoA/Spec Sheet and any accompanying screening reports.

Guidance (general, for discovery use only):

• If used in screening, determine preliminary specificity via counterscreens against close homologs, off-target panels, and orthogonal assay modalities.
• Employ thermal shift or SPR/MST/ITC to quantify binding and derive KD/thermodynamic signatures, followed by mechanistic enzymology (if applicable) to assign MOA.

No claims of therapeutic selectivity or clinical efficacy are made or implied.